Long-term retrospective effects of add-on finerenone therapy in patients with diabetic kidney disease

Impact of add-on finerenone therapy on the 2-year rate of renal function decline and albuminuria in patients with diabetic kidney disease receiving SGLT2 inhibitor treatment: A retrospective observational study - FINER-DKD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061789

Enrollment

Registered

2026-06-05

Start date

2026-06-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus with diabetic kidney disease (DKD)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with type 2 diabetes mellitus Patients with diabetic kidney disease (DKD) Patients newly initiated on finerenone while receiving SGLT2 inhibitor therapy Availability of eGFR data for at least 12 months before finerenone initiation Availability of follow-up data for at least 24 months after finerenone initiation

Exclusion criteria

Exclusion criteria: Patients receiving dialysis therapy Patients with a history of kidney transplantation Patients with acute kidney injury Patients with missing data required for analysis

Design outcomes

Primary

Measure	Time frame
eGFR slope (mL/min/1.73 m2/year) during the 2 years following initiation of finerenone therapy	—

Secondary

Measure	Time frame
Comparison of eGFR slope before and after finerenone initiation Annual eGFR slope during years 0-1 and 1-2 after finerenone initiation Longitudinal changes in urinary albumin-to-creatinine ratio (UACR) Proportion of UACR responders (30% or greater reduction from baseline) Renal outcomes according to baseline eGFR categories Safety outcomes, including changes in serum potassium levels, incidence of hyperkalemia, acute decline in eGFR, and discontinuation rate of finerenone	—

Measure

Time frame

Comparison of eGFR slope before and after finerenone initiation Annual eGFR slope during years 0-1 and 1-2 after finerenone initiation Longitudinal changes in urinary albumin-to-creatinine ratio (UACR) Proportion of UACR responders (30% or greater reduction from baseline) Renal outcomes according to baseline eGFR categories Safety outcomes, including changes in serum potassium levels, incidence of hyperkalemia, acute decline in eGFR, and discontinuation rate of finerenone

—

Countries

Japan

Contacts

Public ContactYuji Kawaguchi

Minami Osaka hospital internal medicine

y.kawaguchi@minamiosaka.com0666850221

Outcome results